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Abstract 
Background: The deep subcutaneous adipose tissue (dSAT) is closely related to the obesity‑associated complica‑
tions similarly to the characteristics of visceral adipose tissue (VAT). However, the association between dSAT and 
metabolic syndrome (MS) is unclear. The purpose of our study was to evaluate the association of distinct abdominal 
adipose tissue with the cardiometabolic risk factors and MS.
Methods: Abdominal computed tomography (CT) images were obtained in 365 asymptomatic subjects (187 sub‑
jects with MS and 178 without MS). The axial images segmented into superficial and deep SAT by manually tracing 
the fascia superficialis at L4–5 levels. The concentrations of serum inflammatory cytokines and adipokines were also 
measured.
Results: The MS group had significantly lower adiponectin levels but significantly higher levels of resistin, leptin, 
tumor necrosis factor‑alpha (TNF‑α), interleukin‑6 (IL‑6), intercellular adhesion molecule (ICAM), monocyte chemo‑
tactic protein‑1 (MCP‑1), and oxLDL than the control group (p < 0.05). All inflammatory cytokines and adipokines 
were associated with the sum of VAT and dSAT areas (VDAT) (P for trend < 0.05), but no significant correlation was 
found between inflammatory cytokines and sSAT. dSAT was significantly associated with MS in both men and women 
(OR 2.371; p < 0.001) whereas the ORs between sSAT and MS were not significant (p = 0.597). The age‑adjusted ORs 
between VDAT and MS (OR of 8.359 in men and 3.183 in women, p < 0.001) were higher than those of VAT (OR of 
7.941 in men and 2.570 in women, p < 0.05) and dSAT (OR of 2.954 in men and 1.856 in women, p < 0.05).
Conclusions: We demonstrated that dSAT was associated with increased inflammation and oxidative stress, suggest‑
ing that dSAT is an important determinant of MS. Therefore, abdominal subcutaneous fat should be considered as 
two functionally distinct compartments rather than a single entity.
Keywords: Superficial subcutaneous adipose tissue, Deep subcutaneous adipose tissue, Visceral adipose tissue, 
Metabolic syndrome, Inflammatory cytokine, Adipocytokine
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Background
Metabolic syndrome (MS) is a cluster of risk factors for 
type 2 diabetes and cardiovascular disease and is asso-
ciated with increased mortality [1]. Although visceral 
adipose tissue (VAT) has been recognized as a key deter-
minant of MS and is presumed to play an important role 
in its development [2, 3], the role of subcutaneous adi-
pose tissue (SAT) is not well understood.
Abdominal SAT can be divided into superficial SAT 
(sSAT) and deep SAT (dSAT) by the fascial plane. dSAT 
has been reported to differ from sSAT morphologically 
and metabolically. Most of the dSAT is located in the pos-
terior half of the abdomen, and the rate of lipolysis, lipo-
genesis, and inflammatory protein expression is higher 
in dSAT than in sSAT [4–6]. The fat lobules of these two 
subcompartments also differ in that sSAT is character-
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compact fascial septa, whereas the dSAT contains larger, 
less organized, and more vascularized lobules [7].
In general, dSAT is closely related to the pathophysiol-
ogy of obesity complications in a manner nearly equiva-
lent to the characteristics of VAT, while sSAT follows the 
pattern of lower-body SAT [8–10]. However, a debate has 
arisen regarding the relative contributions of dSAT com-
pared with VAT in relation to MS. Although some previ-
ous studies suggested that the excessive deposit of dSAT 
results in abnormal lipid profiles and insulin resistance 
[11–13], the correlation of dSAT with cardiometabolic 
risk factors and MS was inconsistent [14, 15]. Therefore, 
the potential association between dSAT and the develop-
ment of obesity-associated complications is still unclear. 
However, few studies have evaluated the distinct abdomi-
nal adipose tissue compartments associated with MS, 
cardiometabolic risk factors, and the expression of vari-
ous cytokines.
The purpose of our study was 1) to examine the differ-
ences between sSAT and dSAT in relation to cardiomet-
abolic risk factors and MS; 2) to determine the levels of 
various adipose tissue-derived cytokines in subjects with 
MS; 3) to evaluate the association of distinct abdominal 
adipose tissue compartments with the levels of inflam-
matory cytokines and adipokines.
Methods
Subjects
A total of 365 asymptomatic subjects (187 patients with 
MS and 178 subjects without MS) were recruited from 
the outpatient clinics at St. Paul’s Hospital, Uijeongbu St. 
Mary Hospital and St. Vincent’s Hospital in South Korea. 
All subjects received comprehensive health screening and 
underwent abdominal CT scans for screening purposes 
between September 2009 and March 2013. Subjects who 
underwent abdominal surgeries affecting the visceral fat 
distribution were excluded from the study. This study was 
approved by the Research Ethics Committee of the Col-
lege of Medicine, The Catholic University of Korea, and 
written informed consent was obtained from all patients.
Risk factor assessment and measurement of serum 
adipokine levels
The anthropometric, clinical and laboratory investi-
gations were performed on all subjects. The height of 
each participant was determined using a fixed wall-
scale measuring device and was measured to the nearest 
0.1  cm. The body weight was measured to the near-
est 0.1  kg using a digital scale calibrated prior to each 
measurement. The body mass index (BMI, kg/m2) was 
calculated as the weight in kilograms (kg) divided by the 
square of height in meters. Waist circumference (WC) 
was measured twice to the nearest centimeter at the end 
of normal expiration in a horizontal plane immediately 
superior to the left iliac crest according to the National 
Health and Nutrition Examination Survey protocols. 
If the variation between these two measurements was 
greater than 2 cm, a third measurement was taken and 
the mean was calculated using the two closest measure-
ments. Seated blood pressures were measured using a 
mercury sphygmomanometer after a 10 min rest period. 
Two blood pressures measurements were taken from 
all subjects with a 5 min interval and were averaged for 
analysis.
Blood samples were drawn in the morning hours after 
a 12-h overnight fast. The samples were left at room tem-
perature for 30 min, centrifuged for 15 min at 2500 rpm 
to separate the serum, and then stored at −70  °C. Fast-
ing serum glucose, total cholesterol, triglyceride, and 
HDL-cholesterol were determined using an autoanalyzer 
(Hitachi 747 auto-analyzer, Hitachi, Tokyo, Japan). Insu-
lin was measured by enzyme immunoassay (Immulite 
2000, SIEMENS, IL, USA).
The concentrations of serum adiponectin, resistin, lep-
tin, intercellular adhesion molecule (ICAM), monocyte 
chemotactic protein-1 (MCP-1), tumor necrosis factor-
alpha (TNF-α), and interleukin-6 (IL-6) were measured 
in duplicate using enzyme-linked immunosorbent assay 
(ELISA) kits (Quantikine, R&D Systems, Minneapolis, 
MN, USA). The mean intra-assay and inter-assay coef-
ficients of variation (CVs) of the adipokines and inflam-
matory cytokines analyzed were as follows: adiponectin 
(<4.7 %, <6.9 %), resistin (<5.3 %, <9.2 %), leptin (<3.3 %, 
5.4 %), ICAM (<5.2 %, <7.8 %), MCP-1 (<7.8 %, <6.8 %), 
TNF-α (<5.2 %, 7.4 %), and IL-6 (<7.8 %, 9.6 %). A solid-
phase two-site enzyme immunoassay (Mercodia Oxi-
dized LDL ELISA, Mercodia, Uppsala, Sweden) was used 
to quantitatively measure oxidized low-density lipopro-
teins (oxLDL) in serum.
Criteria for metabolic syndrome
MS was defined according to the revised NCEP-ATP III 
criteria with an ethnic-specific cutoff point for abdomi-
nal obesity [16]. Diagnosis of MS was based on the pres-
ence of three or more of the following clinical criteria: (1) 
WC ≥90 cm for men or ≥85 cm for women; (2) TG lev-
els ≥150 mg/dl; (3) HDL-cholesterol levels <40 mg/dl for 
men or  <50  mg/dl for women; (4) SBP ≥130  mmHg or 
DBP ≥85 mmHg, or the use of antihypertensive medica-
tion; and (5) FBS ≥100 mg/dl, or the use of anti-diabetics 
or insulin.
Measurement of abdominal adipose tissue by CT
To assess abdominal fat distribution, approximately 
4–5 continuous transverse images (120  kV, 200  mA, 
scanning time of 2  s, field of view of 380 mm, and slice 
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thickness 5 mm) were obtained at the level of the L4–5 
intervertebral space using a CT scanner (LightSpeed, 
GE Healthcare, Milwaukee, WI). The cross-sectional 
areas of adipose tissue were measured by one experi-
enced observer blinded to the clinical information of the 
study subjects. The segmentation of the axial images into 
superficial and deep SAT areas were performed by manu-
ally tracing the fascia superficialis at the L4–5 interver-
tebral space (Fig. 1). The pixels with a threshold range of 
−190 to −30 Hounsfield units (HU) were calculated for 
each area of adipose tissue. Visceral and deep subcuta-
neous adipose tissue (VDAT) area was calculated as the 
sum of VAT and dSAT areas. All CT analyses were per-
formed using a dedicated offline workstation (Rapidia, 
software version 2.8, Infinitt, Seoul, Korea).
Statistical analysis
Data were analyzed using SPSS version 21.0 (SPSS Inc., 
Chicago, IL) and presented as mean  ±  standard devia-
tion (SD). The values of fasting plasma glucose, TG, 
and cytokines (adiponectin, resistin, leptin, ICAM, 
MCP-1, oxLDL, TNF-α, and IL-6) were highly skewed, 
thus, log-transformed for all analyses. Sex-specific, age-
adjusted Pearson correlation coefficients were used to 
assess simple correlations between adipose tissue areas 
and the cardiometabolic risk factors. Analysis of covari-
ance (ANCOVA) adjusted for gender and age was used 
to compare serum cytokine concentrations according 
to VDAT, VAT, dSAT, and sSAT tertiles. Multiple logis-
tic regression analysis was performed to assess the rela-
tionships between each adipose tissue area and MS. 
Odds ratios (ORs) for MS were based on a 1-SD increase 
in each of the VDAT, VAT, dSAT, and sSAT areas. A 
two-sided p value  <0.05 was considered statistically 
significant.
Results
Baseline characteristics of the study participants
Table  1 summarizes the baseline characteristics of the 
study participants. There was no significant differ-
ence in sex, age, and smoking status between the two 
groups. BMI (22.98  ±  3.84  kg/m2 vs. 27.24  ±  3.84  kg/
m2, p  <  0.001) and WC (82.29 ±  8.24 vs. 94.98 ±  6.82, 
p  <  0.001) were significantly higher in the MS group 
than in the control group. Similarly, the VAT and SAT 
areas were greater in the MS group than in the control 
group (p < 0.05). The ratio of dSAT to total adipose tissue 
(TAT) area was higher in men than in women whereas 
the ratio of sSAT/TAT area was higher in women than 
in men (0.367 ±  0.097 vs. 0.245 ±  0.09, p < 0.001, data 
not shown). The MS group showed significantly higher 
glucose, TG, blood pressure, insulin, and HOMA-IR val-
ues and lower HDL cholesterol levels than the control 
group (p  <  0.05). The MS group had significantly lower 
adiponectin levels (p < 0.001) but significantly higher lev-
els of resistin, leptin, TNF-α, IL-6, ICAM, MCP-1, and 
oxLDL than the control group (p < 0.05).
Correlations with cardiometabolic risk factors
The correlations between adipose tissue area and car-
diometabolic risk factors are shown in Table  2. All car-
diometabolic risk factors were significantly correlated 
with VAT except for diastolic blood pressure in men. 
The dSAT area in men and women had similarly high 
correlations with most of the cardiometabolic risk fac-
tors. Waist circumference (WC) was significantly cor-
related with all subdivisions of abdominal adiposity but 
was more strongly associated with VAT and dSAT than 
with sSAT. The correlation coefficients of fasting blood 
glucose (r = 0.489, p < 0.001), TG (r = 0.553, p < 0.001), 
HDL (r = −0.579, p < 0.001), and systolic blood pressure 
Fig. 1 Measurement of deep and superficial subcutaneous adipose tissue area by cross‑sectional abdominal computed tomography (CT) scans. 
The fascia superficialis (arrowhead) was used to separate superficial and deep compartments from SAT (a). The measurement of adipose tissue area 
was performed by tracing the fascia superficialis in the transverse CT image. After drawing the region of interest (ROI), the pixels with a threshold 
range of −190 to −30 Hounsfield units (HU) were identified as each adipose tissue area (b, c) as follows: red color superficial subcutaneous fat; blue 
deep subcutaneous fat; black visceral adipose tissue
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(SBP) (r =  0.316, p  <  0.01) with VAT were higher than 
those with dSAT in men (r =  0.351, 0.209, −0.321, and 
0.306, respectively, p < 0.05). Glucose and SBP were also 
correlated with the area of sSAT in men, but weak in 
comparison to dSAT. We did not find significant correla-
tions of fasting blood glucose, TG, and HDL with dSAT 
and sSAT in women.
Comparison of the cytokine levels according to abdominal 
adiposity
We divided subjects into tertiles according to the sub-
divisions of abdominal adiposity. All inflammatory 
cytokines were associated with increasing VDAT tertile, 
but no significant correlation was found between inflam-
matory cytokines and sSAT in males and females (p for 
trend  <0.05, Figs.  2, 3). In male, significant associations 
were observed between dSAT tertiles and most of the 
inflammatory cytokines and adipokines (p < 0.05, Fig. 2). 
Leptin, L/A ratio, and resistin increased linearly with each 
increase in dSAT tertile: leptin levels were 4.493 ± 4.46, 
4.392 ± 2.73, and 5.577 ± 3.72 for the first, second, and 
third dSAT tertiles, respectively (p = 0.002); resistin lev-
els for dSAT tertiles were 6.149 ± 3.49, 7.618 ± 3.24, and 
9.213  ±  4.40, respectively (p  <  0.001). In addition, the 
serum level of adiponectin decreased with each tertile 
increase in VAT and dSAT: adiponectin for each dSAT 
tertile were 5.679 ± 2.76, 4.755 ± 2.21, and 4.683 ± 2.70, 
respectively (p = 0.032). Similarly, inflammatory cytokine 
concentrations increased with each increase in dSAT ter-
tile except for IL-6 and MCP-1.
In female, Leptin, IL-6, ICAM and MCP-1 increased 
linearly with each increase in dSAT tertile (p  <  0.05, 
Fig.  3). While the serum level of adiponectin decreased 
with increase in dSAT tertile, no significant differ-
ences were found between the tertiles: adiponectin for 
each dSAT tertile were 6.74  ±  3.12, 6.454  ±  2.63, and 
6.02  ±  2.67, respectively (p  =  0.643). Most of inflam-
matory cytokine concentrations increased with each 
increase in VAT tertile except for TNF-α.
Association between abdominal adipose tissue 
subcompartments and MS
The association between each adipose tissue area and 
MS was assessed using multivariate logistic regression 
models (Table 3). dSAT was significantly associated with 
MS in both men and women (OR 2.371; 95 % CI 1.563–
3.594; p < 0.001) whereas the ORs between sSAT and MS 
were not significant (p =  0.597). The age-adjusted ORs 
between VDAT and MS (OR of 8.359 in men and 3.183 
in women, p < 0.001) were higher than those of VAT (OR 
of 7.941 in men and 2.570 in women, p < 0.05) and dSAT 
(OR of 2.954 in men and 1.856 in women, p < 0.05).
Discussion
In this study, dSAT as well as VAT was associated with 
MS in both men and women. The CT measurements 
of dSAT were well correlated with multiple metabolic 
risk factors, and these risk factors were more strongly 
Table 1 General characteristics of  the study subjects 
(N = 365)
Values are expressed as the mean ± SD (standard deviation), n number of 
subjects, BMI body mass index, WC waist circumference, SBP systolic blood 
pressure, DBP diastolic blood pressure, VAT visceral adipose tissue, DSAT deep 
subcutaneous adipose tissue, SSAT superficial subcutaneous adipose tissue, 
TNF-α tumor necrosis factor-alpha, IL-6 interleukin-6, ICAM intercellular adhesion 
molecule, MCP-1 monocyte chemoattractant protein 1, oxLDL oxidized low-
density lipoprotein, L/A leptin to adiponectin ratio
* Statistical significance was tested using independent t-tests or χ2  test
Normal control 
(n = 178)
MS group  
(n = 187)
p value*
Male 91 (51.12 %) 107 (57.21 %) 0.250
Age (year) 51.208 ± 17.315 54.439 ± 14.344 0.054
Smoking status 0.341
 Never/ex‑smokers 139 (78.09 %) 156 (83.42 %)
 Current smokers 39 (21.91 %) 31 (16.58 %)
Weight (kg) 61.595 ± 11.416 74.796 ± 14.067 <0.001
BMI (kg/m2) 22.985 ± 3.849 27.241 ± 3.841 <0.001
WC (cm) 82.296 ± 8.240 94.980 ± 6.821 <0.001
Glucose (mg/dL) 104.440 ± 38.161 114.934 ± 28.573 0.003
Triglyceride  
(mg/dL)
104.511 ± 56.979 187.348 ± 111.942 <0.001
HDL cholesterol  
(mg/dL)
53.836 ± 15.370 43.743 ± 11.334 <0.001
SBP (mm Hg) 119.483 ± 12.779 134.953 ± 16.053 <0.001
DBP (mm Hg) 71.730 ± 9.423 78.443 ± 13.344 <0.001
Insulin (µU/mL) 7.301 ± 6.730 11.677 ± 9.820 <0.001
HOMA‑IR 1.883 ± 1.905 3.426 ± 3.405 <0.001
VAT (cm2) 78.041 ± 40.241 155.411 ± 52.241 <0.001
DSAT (cm2) 74.345 ± 34.487 113.896 ± 47.868 <0.001
SSAT (cm2) 80.891 ± 45.847 98.456 ± 48.189 0.001
SAT (cm2) 151.120 ± 73.331 211.384 ± 81.868 <0.001
Adiponectin  
(µg/mL)
6.306 ± 2.898 5.453 ± 5.228 <0.001
Resistin (ng/mL) 6.657 ± 4.006 8.614 ± 4.011 0.047
Leptin (ng/mL) 6.136 ± 6.474 6.656 ± 5.574 0.015
TNF‑α (pg/mL) 3.402 ± 3.895 6.676 ± 5.707 0.003
IL‑6 (pg/mL) 2.613 ± 1.995 3.306 ± 1.532 0.004
ICAM (ng/mL) 118.062 ± 48.877 166.617 ± 65.287 <0.001
MCP‑1 (pg/mL) 245.731 ± 80.592 304.719 ± 92.347 <0.001
oxLDL (U/L) 65.043 ± 16.715 85.536 ± 21.876 <0.001
L/A 1.301 ± 1.755 1.739 ± 1.918 0.024
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correlated with dSAT than with sSAT. In addition, a sig-
nificant association was observed between dSAT and 
most of the inflammatory cytokines and adipocytokines 
but no significant correlations were found with sSAT. 
Moreover, dSAT was significantly associated with MS in 
both men and women but the ORs between sSAT and 
Table 2 Partial correlation coefficients between metabolic risk factors and adipose tissue areas (age-adjusted)
VAT visceral adipose tissue, DSAT deep subcutaneous adipose tissue, SSAT superficial subcutaneous adipose tissue, WC waist circumference, SBP systolic blood 
pressure, DBP diastolic blood pressure, HOMA-IR homeostasis model assessment of insulin resistance
* p < 0.001, ** p < 0.01, *** p < 0.05
Male Female
VAT dSAT sSAT VAT dSAT sSAT
WC (cm) 0.732* 0.753* 0.549* 0.700* 0.634* 0.623*
Glucose (mg/dL) 0.489* 0.351** 0.246*** 0.386** 0.191 0.119
Triglyceride (mg/dL) 0.553* 0.209*** 0.271*** 0.497*** 0.063 0.135
HDL cholesterol (mg/dL) −0.579* −0.321** −0.138 −0.485*** −0.222 −0.130
SBP (mmHg) 0.316** 0.306** 0.214*** 0.340** 0.464* 0.317**
DBP (mmHg) 0.146 0.095 0.206 0.302** 0.381* 0.249***
Insulin 0.307** 0.374* 0.415* 0.517* 0.241*** 0.281***
HOMA‑IR 0.360** 0.404* 0.427* 0.536* 0.251*** 0.280***
Fig. 2 Comparison of the cytokine levels according to the subdivisions of abdominal adiposity in male. The areas of visceral and deep subcutane‑
ous adipose tissue (VDAT), visceral adipose tissue (VAT), deep subcutaneous adipose tissue (dSAT), and superficial subcutaneous adipose tissue 
(sSAT) were divided into tertiles for comparison of various cytokines. Values are expressed as mean ± standard error of the mean
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MS were not significant. These results suggest that dSAT 
may contribute to the obesity-related complications in a 
nearly same pattern to that observed for VAT.
Many previous studies have demonstrated that VAT is 
strongly associated with cardiometabolic risk factors and 
MS. However, there is a controversy as to whether VAT 
alone is responsible for the metabolic complications due 
to obesity. Although several investigators have reported 
that SAT may also contribute to MS and insulin resist-
ance [10, 17–19], the correlation between SAT and MS 
was inconsistent. This inconsistency may result from the 
study of metabolically unhealthy dSAT. However, only a 
few studies have evaluated the cardiometabolic risk of 
dSAT so far, and the results were inconsistent accord-
ing to the study populations. Some investigators have 
reported a significant association between dSAT and 
insulin sensitivity [6, 9, 12], non-alcoholic steatohepa-
titis [20], and adverse lipid and glycemic profiles [8, 11]. 
In contrast, other studies found no correlation of dSAT 
with postprandial TG and lipid profile in patients with 
coronary artery disease or type 2 diabetes mellitus [14, 
15]. This conflicting result might be due to differences 
in sample size and inclusion criteria. Our study demon-
strated that dSAT as well as VAT were associated with 
MS, and showed a strong correlation with most meta-
bolic risk factors compared with sSAT. Indeed, dSAT 
was significantly associated with MS in both men and 
women, whereas the ORs between sSAT and MS were 
not significant (p = 0.597). Furthermore, the age-adjusted 
ORs between VDAT and MS were higher than those of 
VAT or dSAT, and all inflammatory cytokines were also 
associated with increasing VDAT tertile. These findings 
suggest that the sum of VAT and dSAT rather than VAT 
alone would be a better predictor for metabolic compli-
cation that is not completely explained by VAT or dSAT.
In this study, ORs of dSAT for MS and the correlations 
between dSAT and metabolic risk factors were higher 
in men than in women. Furthermore, the association 
between dSAT tertiles and the inflammatory cytokines 
was more apparent in men than in women. Such findings 
Fig. 3 Comparison of the cytokine levels according to the subdivisions of abdominal adiposity in female. The areas of visceral and deep subcuta‑
neous adipose tissue (VDAT), visceral adipose tissue (VAT), deep subcutaneous adipose tissue (dSAT), and superficial subcutaneous adipose tissue 
(sSAT) were divided into tertiles for comparison of various cytokines. Values are expressed as mean ± standard error of the mean
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are similar to that of a previous study, which reported 
that dSAT was more weakly associated with health risks 
in women compared with men [9, 21, 22]. However, the 
reasons for the more strong association of dSAT with 
various cytokines and MS in men remain unclear; the 
relatively small sample size of women compared to men 
in this study might not fully explain this finding. The 
cause of these sex differences may be related to a twofold 
higher rate of free fatty acid mobilization from fat cells 
by norepinephrine stimulation in men compared with 
women [23]. Another possible explanation is the differ-
ence in sexually dimorphic subcutaneous fat distribution. 
Consistent with previous study [8, 9], the sSAT to TAT 
ratio in the present study was higher in women than in 
men, and the relatively large amount of sSAT in women 
might attenuate the influence of VAT and dSAT on the 
association with MS and cytokines in women as com-
pared to men. Considering ethnic difference of fat dis-
tribution, further studies are need to clarify whether our 
findings in sex differences are limited to Korean popula-
tion or generalized to Asian populations.
It is well known that adipose tissue produces vari-
ous cytokines, such as resistin, leptin, adiponectin, IL-6, 
TNF-α, and MCP-1. The excessive secretion of inflam-
matory cytokines and decreased secretion of defensive 
adipocytokines, such as adiponectin, may cause obesity-
related chronic or low-grade systemic inflammation [24]. 
The MS group had significantly lower adiponectin levels 
but significantly higher levels of resistin, leptin, TNF-α, 
IL-6, ICAM, MCP-1, and oxLDL compared with the con-
trol group. Moreover, most cytokines were similarly asso-
ciated with VAT and dSAT but not with sSAT. This trend 
could be explained by metabolically active deep sub-
cutaneous adipocytes. It has been well established that 
inflammatory, lipogenic, and lipolytic genes are overex-
pressed in dSAT [7], reflecting the protein expression 
characteristics of VAT [4, 6]. In addition, the percentage 
of small adipocytes and saturated fatty acids increases 
in dSAT [7, 25], which indicates decreased fat storage 
capacity, leading to excessive inflammation [26]. To the 
best of our knowledge, this is the first study in which 
various cytokines have all been investigated in relation to 
SAT subcompartment distribution and MS.
Although adiponectin is considered an important 
modulator of MS to overt atherosclerosis [27], little 
is known about the relationship between adiponectin 
and dSAT. Some previous studies found no correlation 
between plasma adiponectin levels and SAT [28, 29]. On 
the contrary, other studies showed an inverse association 
between adiponectin and SAT [17, 30, 31]. These incon-
sistent findings may result from methodological limita-
tions of the measurement of adipose tissue area using 
CT, combining two different types of SAT into a single 
entity. In our study, adiponectin levels were negatively 
associated with VAT and dSAT areas but not associated 
with sSAT, more pronounced for men. In contrast, serum 
leptin level was positively associated with both SAT sub-
compartments, and L/A ratio was correlated with most of 
adipose tissue parameters. The result of our study implies 
that adiponectin is a more specific biomarker for meta-
bolically unhealthy obese (MUHO) than leptin and L/A 
ratio. Regarding the gender difference, our results are in 
line with the previous studies [21, 22], and explained by 
the predominant dSAT deposition and the lower expres-
sion of adiponectin in male compared to female subjects. 
Contrary to our results, one recent study on SAT sub-
compartments had demonstrated sSAT-specific down-
regulation of adiponectin and increase of inflammatory 
cytokines [31]. However, this study evaluated the expres-
sion of proteins from adipose tissue with the relatively 
small number of subjects. Considering the differences 
between circulating level and the adipose tissue expres-
sion of cytokines, further studies are required to clarify 
the role of sSAT on metabolic complication.
In this study, serum TNF-α concentration was simi-
larly associated with VAT and dSAT in male, but not in 
female. Consistent with our findings, Koistinen et  al. 
reported that subcutaneous adipose tissue TNF-α mRNA 
level correlated with BMI in men but not in women [32]. 
However, the systemic release of TNF-α is variable, thus 
Table 3 Multiple logistic regression analysis of  metabolic 
syndrome
Age-adjusted odds ratios (ORs) and 95 % confidence intervals (CIs) are presented 
as odds for metabolic syndrome with 1 SD increase in abdominal adipose tissue 
areas
VDAT the sum of visceral and deep subcutaneous adipose tissue, VAT visceral 
adipose tissue, dSAT deep subcutaneous adipose tissue, sSAT superficial 
subcutaneous adipose tissue
B SE OR 90 % CI p value
Total
 VDAT 1.628 0.184 5.094 3.55–7.31 <0.001
 VAT 1.568 0.202 4.795 3.228–7.124 <0.001
 dSAT 0.863 0.212 2.371 1.563–3.594 <0.001
 sSAT 0.098 0.186 1.103 0.766–1.588 0.597
Male
 VDAT 2.123 0.306 8.359 4.591–15.219 <0.001
 VAT 2.072 0.350 7.941 3.998–15.771 <0.001
 dSAT 1.083 0.376 2.954 1.413–6.178 0.004
 sSAT 0.054 0.384 1.055 0.497–2.240 0.888
Female
 VDAT 1.158 0.231 3.183 2.023–5.008 <0.001
 VAT 0.944 0.272 2.570 1.508–4.380 0.001
 dSAT 0.618 0.264 1.856 1.107–3.111 0.019
 sSAT −0.103 0.271 0.902 0.531–1.534 0.705
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abdominal adiposity may not influence peripheral TNF-α 
concentrations [33, 34]. For oxLDL and resistin, the 
serum levels increased in the MS group compared with 
the control group. In addition, oxLDL and resistin levels 
increased with each increase in VAT and dSAT tertile in 
male. In contrast to this result, some previous studies had 
demonstrated that VAT is correlated with plasma oxLDL 
level but not with SAT [35, 36]. In addition, the relation-
ship between resistin levels and abdominal SAT distri-
bution has been also inconsistent and unclear. Although 
Utzschneider et al. reported a correlation between resis-
tin levels and BMI and SAT [37], other studies found no 
association between resistin levels and obesity [38, 39] 
or SAT [40]. However, these studies measured abdomi-
nal fat depositions only in small subjects and did not 
separate SAT into superficial and deep compartments. 
Considering the metabolic differences between dSAT 
and sSAT, our study clearly indicates that dSAT as well 
as VAT may play an important role in systemic oxidative 
stress and MS.
There are some limitations in this study. First, our find-
ings may not be applicable to the general population 
because of the relatively small sample size. Furthermore, 
we did not take into account the levels of physical activ-
ity and menopausal state, both of which may affect vis-
ceral adiposity. Second, we performed a cross-sectional 
study, and could not determine causality between dSAT 
and MS. Third, although total adiponectin levels were 
negatively associated with VAT and dSAT, we did not 
measure the high molecular weight (HMW) adiponec-
tin, the active forms of adiponectin. Fourth, we measured 
AT area in a single cross-sectional image rather than AT 
volume. Although multislice volume imaging is generally 
considered gold standard for measuring adipose tissue 
volumes, its application is limited by radiation exposure 
associated with multislice CT. Accordingly, most inves-
tigators use a single cross-sectional image at the level of 
L4–5 intervertebral space to assess abdominal adipos-
ity, which is known to well correlate with AT volume. 
Moreover, our study design has strength in allowing for 
an exact analysis of abdominal SAT distribution by ana-
tomical landmark, providing robust evidence for measur-
ing dSAT to assess cardiometabolic risk.
Conclusions
In this study, we demonstrated that dSAT was associated 
with MS, increased inflammation, and oxidative stress, 
suggesting that dSAT is an important determinant of MS. 
Therefore, from the perspective of early effective inter-
vention for MS, abdominal subcutaneous fat should be 
considered as two functionally distinct compartments 
rather than a single entity. Further prospective studies 
are required to determine the correlations between these 
compartments and metabolic risk factors over time in 
order to evaluate the influence of dSAT on cardiometa-
bolic risk.
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